Integra Lifesciences Holdings (IART) Tops Q3 EPS by 9c; Adjusts FY12 EPS Outlook
Integra Lifesciences Holdings (NASDAQ: IART) reported Q3 EPS of $0.85, $0.09 better than the analyst estimate of $0.76. Revenue for the quarter came in at $210.1 million versus the consensus estimate of $211.51 million.
Integra Lifesciences Holdings sees FY2012 EPS of $3.04-3.09, versus the consensus of $3.04.
For earnings history and earnings-related data on Integra Lifesciences Holdings (IART) click here.
Integra Lifesciences Holdings sees FY2012 EPS of $3.04-3.09, versus the consensus of $3.04.
For earnings history and earnings-related data on Integra Lifesciences Holdings (IART) click here.
